ClinicalTrials.gg
RecruitingNCT06155266CYTOBACTUpdated Jan 13, 2025

Combination of Leukocyte Cell Surface Biomarkers Measured by Cytometry, to Differentiate Bacterial From Viral Infections in Emergency Department: a Multicentric Cohort for the Validation of Diagnostic Performances

An observational study in Bacterial and Viral Infections, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Virus Diseases by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Virus Diseases · Assistance Publique - Hôpitaux de Paris.

Started
2024
the only one that year
Observational
7 of 12
3 open now
Registered
10th of 12
by date

Among the 12 studies in Virus Diseases by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 7 observational ones, and was the 10th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

3 of the 12 studies in Virus Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Virus Diseases by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The characterization of the bacterial or viral etiology of an infectious event is required for both isolation decisions and rationale use of antibiotics. In emergency room (ER), the direct identification of the causal pathogen is rarely available in real-time. Alternative is the identification of the host-response to either a bacterial or viral infection. One of this host-response is the expression of peripheral leukocytes cell surface markers, measured by flow cytometry. Investigators and others have reported the high diagnostic performances of combination of cell surface biomarkers to differentiate bacterial from viral infection. The CYTOBACT study aims to confirm on a 500 patients multicentric cohort (200 having already been collected during another study: SEPTIMET), the best combinations for this diagnostic issue.

The study will be conducted in 3 emergency departments of APHP hospitals network in Paris, France. Patients with a suspicion of infection will be proposed to participate. No intervention will be introduced during the routine care in the (ER) which will be let at the discretion of the treating emergency physician. During the routine blood sampling in the ER, an additional 30 ml volume of whole blood will be collected, centrifugated, aliquoted and stored at -80°C for further measurement of the expression of a panel of cell surface markers. The participants will be followed up during their hospitalization (if any) and no longer than 28 days. Clinical data at admission, usual blood tests and all microbiological investigations performed during the hospital stay will be recorded into an electronic case record form (eCRF). Based on all those recorded data (excepted the results of flow cytometry for cell surface biomarkers) 2 independent adjudicators will qualify the infectious episode into bacterial,viral or no infection, and (if any) into infection, sepsis or septic shock (according to Sepsis 3.0 definitions).

Using different "machine learning" statistical tools, all the combination of the cell surface biomarkers will be tested to select those with the highest performance to differentiate bacterial from viral infection.

Read the detailed description

Patients attending the ED of one of the participant centers for a suspicion of infection will be informed and asked to participate. After obtaining a non-opposition to participate, during the routine blood sampling performed in the ER, an additional volume of 30 ml of whole blood will be collected, aliquoted and stored at -80°C, comprising notably 12 ml of whole blood to which 1 ml of Cytodelics® Stabiliser will be added and incubated à room temperature for 10 mn before being aliquoted and stored at -80°C. The remaining whole blood will be collected on EDTA and Paxgen tubes, centrifugated, aliquoted and stored at -80°C for blood collection.

Clinical data at admission (past medical history, vital parameters, infectious source (if any), treatments delivered in the ER) will be recorded into an eCRF. The participants will be followed up until leaving the hospital and no longer than day-28. All the microbiology tests performed during the hospital stay will be also recorded into eCRF. The diagnostic performance of the combinations of cell surface markers will be evaluated against a diagnostic reference on the bacterial of viral qualification of each infectious event. This diagnostic reference will be established by an independant expert comitee after reviewing all the clinical, and biological data recorded (excepted the results of flow cytometry), in order to adjudicate between bacterial, viral or no infection, and among infected patients to classify into infection, sepsis or septic shock (sepsis 3.0).

After completing the recruitement of participants, a panel of cell surface markers will be measured by batch on a spectral cytometer, comprising notably the biomarkers of interest already published : HLA-DR, CD169 and CX3CR1 on monocytes, and MerTk, CD64 and CD24 on neutrophils.

The performances of the combinations of cell surface markers already identified in the littérature will be tested prioritarily. However, in order to refine the best combinations of biomarkers to discriminate bacterial from viral infection, machine learning algorithms like gradient boosting tree and support vector machine tools will be applied on the entire results of cell surface markers measured. The diagnostic performance will be evaluated calculating the sensitivity, specificity, area under the ROC curve of the biomarkers combinations selected.

03

Conditions studied

  • Bacterial and Viral Infections

Keywords

  • Bacterial infection
  • Viral infection
  • Flow cytometry
  • HLA-DR
  • CD64
  • MerTk
  • CD24
  • CX3CR1
  • CD169
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the ER with a suspicion of infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 year-old
  • Attending one of the participant ED from Monday to Friday between 8:30 am to 3:00 pm
  • With a suspicion of infection (defined by either a measured temperature above 38°C or any microbiology diagnostic test ordered during the routine care)
  • Having blood sampling during routine care
  • Informed and having expressed his/her non-opposition to participate

Exclusion criteria

Exclusion Criteria:

    • Pregnancy
  • No social insurance
  • Prisoners
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic test2 additional whole blood samples of 6mL each will be taken

    As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month. Any remaining samples sent to CIMI will be destroyed once the analyses have been completed.

06

What researchers measure

Primary outcomes

  1. performances of cell surface markers combinations for diagnosis

    area under the ROC curve of the different combinations of cell surface biomarkers for the diagnosis of bacterial or viral infection.

    Time frame: through study completion, an average of 15 months

Secondary outcomes

  1. performances of cell surface markers combinations for severity assesment

    area under the ROC curve of the different combinations of cell surface biomarkers for the diagnosis of infetion, sepsis or septic shock

    Time frame: through study completion, an average of 15 months

  2. performances of cell surface markers combinations according to the age range of participants

    area under the ROC curve of the different combinations of cell surface biomarkers in the subgroups 18 to 75 year-old and \>75 year-old for the diagnosis and severity assesment

    Time frame: through study completion, an average of 15 months

07

Study locations

1 of 3 sites recruiting
  • Service des urgences, Lariboisière
    Paris, 75010, France
    Not yet recruiting
  • Service des urgences, Saint-Antoine
    Paris, 75012, France
    Not yet recruiting
  • Service des urgences, Pitié Salpêtrière
    Paris, 75013, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Aug 2025, 15 months after the start.

Of 73 non-industry observational studies under Virus Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 108. This study's planned 15 months is below that.

Counting every sponsor, half of 80 studies reached it within 24 months; a quarter within 8 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Dec 4, 2023
StartActual
May 14, 2024
Primary completionEst.
Aug 14, 2025
CompletionEst.
Aug 14, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06155266
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
May 14, 2024
Primary completion
Aug 14, 2025 (estimated)
Completion
Aug 14, 2025 (estimated)
Last update
Jan 13, 2025

Study contacts

laetitia Velly, MD
Contact
laetitia.velly@aphp.fr
(33)7 82 28 94 91
Pierre Hausfater, MD, PhD
Contact
pierre.hausfater@aphp.fr
(33)6 85 01 30 15

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion